Savara Inc. (SVRA) |
| 4.92 0.09 (1.86%) 10-09 16:00 |
| Open: | 4.82 |
| High: | 4.975 |
| Low: | 4.81 |
| Volume: | 1,528,811 |
| Market Cap: | 1,008(M) |
| PE Ratio: | -8.79 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 5.63 |
| Resistance 1: | 5.24 |
| Pivot price: | 5.00 |
| Support 1: | 4.60 |
| Support 2: | 3.83 |
| 52w High: | 7.01 |
| 52w Low: | 3.35 |
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Financials
| EPS | -0.590 |
| Book Value | 0.560 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.423 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -50.2 |
| Return on Equity (ttm) | -105.5 |
Company news
Thu, 08 Oct 2026
Savara stock gets USD 12 JPMorgan target before FDA date - AD HOC NEWS
Tue, 01 Sep 2026
Will Long-Term IMPALA-2 aPAP Data at ERS 2026 Change Savara's (SVRA) Narrative - Simply Wall Street
Tue, 11 Aug 2026
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Wed, 05 Aug 2026
Savara: High-Potential Binary Bet Cruising To PDUFA After A 3 Month Speed Bump (SVRA) - Seeking Alpha
Thu, 30 Jul 2026
Savara's Inhaled Drug Formulation Gains Protection in Europe, Australia - Stock Titan
Fri, 26 Jun 2026
SVRA Forecast — Price Target — Prediction for 2027 - TradingView
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
